Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
New EVA Application
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
Publ. Version/Full Text
DOI
PMC
 |
Open Access Gold |
|
as soon as is submitted to ZB.
Secreted interferon-inducible factors restrict hepatitis B and C virus entry in vitro.
J. Immunol. Res. 2017:4828936 (2017)
Interferon-α (IFN-α) has been used for more than 20 years as the first-line therapy for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, because it has a number of antiviral effects. In this study, we describe a novel mode of its antiviral action. We demonstrate that the supernatant from IFN-α-treated cultured cells restricted HBV and HCV infection by inhibiting viral entry into hepatoma cells. The factors contained in the supernatant competed with the virus for binding to heparan glycosaminoglycans-the nonspecific attachment step shared by HBV and HCV. Secreted factors of high molecular mass that bind to heparin columns elicited the antiviral effect. In conclusion, IFN-α is able to induce soluble factors that can bind to heparan glycosaminoglycans thus leading to the inhibition of viral binding.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
3.276
1.040
13
18
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Surface Heparan-sulfate; Humanized Mice; Initial Interaction; Envelope Protein; Dengue Virus; Infection; Replication; Binding; Cells; Identification
Language
english
Publication Year
2017
HGF-reported in Year
2017
ISSN (print) / ISBN
2314-8861
e-ISSN
2314-7156
Journal
Journal of Immunology Research
Quellenangaben
Volume: 2017,
Article Number: 4828936
Publisher
Hindawi
Publishing Place
New York, NY
Reviewing status
Peer reviewed
Institute(s)
Institute of Virology (VIRO)
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s)
G-502700-003
PubMed ID
28367455
WOS ID
WOS:000398697100001
Scopus ID
85015955903
Erfassungsdatum
2017-06-08